« Return to News | Clinical Intelligence

Affinium doses first patient with oral AFN-1252 for skin infections

Wednesday, February 1, 2012 04:04 PM

Affinium Pharmaceuticals has dosed its first patient in a multi-center phase II clinical trial evaluating oral AFN-1252 in acute bacterial skin and skin structure infections. The phase II trial is the first human efficacy study conducted with this new class of antibiotic and follows the recently completed phase I trials, which demonstrated excellent safety, tolerability and pharmacokinetics of AFN-1252 in single and multiple ascending oral dosages.

The phase II study will confirm efficacy and tolerability of 200mg of oral AFN-1252 dosed twice daily for five to 14 days in patients with staphylococcal skin infections. The trial will also evaluate both the traditional endpoints at end of treatment and early endpoints currently recommended by the FDA.

"A staphylococcal-specific antibiotic provides the unique benefits of no off-target effects on gut flora and no resistance selection pressure on other bacterial species which greatly reduces the probability of antibiotic associated adverse events such as C. difficile disease, diarrhea or candidiasis, while providing high potency against the desired target,” said Nachum Kaplan, Ph.D., vice president of microbiology at Affinium. “AFN-1252 is like no other antibiotic ever developed, and we look forward to having the phase II data later this year.”

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.